BiotechTube

WVE-120101 + Placebo

Phase 1/2Terminated
0 views this week 0 watching💤 Quiet
Interest: 18/100
18
Hype Score

Development Stage

✓
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Huntington's Disease

Conditions

Huntington's Disease

Trial Timeline

Jul 17, 2017 → May 11, 2021

NCT ID
NCT03225833

About WVE-120101 + Placebo

WVE-120101 + Placebo is a phase 1/2 stage product being developed by WaVe Life Sciences for Huntington's Disease. The current trial status is terminated. This product is registered under clinical trial identifier NCT03225833. Target conditions include Huntington's Disease.

What happened to similar drugs?

1 of 2 similar drugs in Huntington's Disease were approved

Approved (1) Terminated (1) Active (0)
✅TetrabenazineLundbeckApproved
❌SAGE-718Supernus PharmaceuticalsPhase 3

Hype Score Breakdown

Clinical
9
Activity
0
Company
9
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT03225833Phase 1/2Terminated

Competing Products

15 competing products in Huntington's Disease

See all competitors
ProductCompanyStageHype Score
AFQ056 + PlaceboNovartisPhase 2
27
RO7234292 (RG6042)RochePhase 2
35
RG6496 + PlaceboRochePhase 1
36
PF-02545920 + PF-02545920PfizerPhase 2
35
20 mg BID of PF-02545920PfizerPhase 2
27
PF-02545920 + Placebo + PF-02545920 + PlaceboPfizerPhase 2
35
ALN-HTT02 + PlaceboAlnylam PharmaceuticalsPhase 1
33
TetrabenazineLundbeckApproved
36
BN82451B + PlaceboIpsenPhase 2
24
ISIS 443139 10 mg + ISIS 443139 30 mg + ISIS 443139 60 mg + ISIS 443139 90 mg + ISIS 443139 120 mgIonis PharmaceuticalsPhase 1/2
29
WVE-120102 + PlaceboWaVe Life SciencesPhase 1/2
18
SAGE-718Supernus PharmaceuticalsPhase 3
26
SAGE-718 + PlaceboSupernus PharmaceuticalsPhase 2
29
OMS643762 + PlaceboOmeros CorporationPhase 2
21
VX15/2503 + PlaceboVaccinexPhase 2
25